摘要
目的评估左旋氨氯地平+缬沙坦应用在轻、中度原发性高血压(essential hypertension,EH)患者中的临床疗效。方法方便选取2021年1月—2022年3月潍坊市第二人民医院心血管内科收治的88例轻、中度EH患者为研究对象,随机数表法分为对照组(44例,采用左旋氨氯地平治疗方案)和观察组(44例,采用左旋氨氯地平+缬沙坦治疗方案),比较组间血压、心率(HR)、治疗有效率、药品不良反应(adverse drug reaction,ADR)。结果治疗3个月后,观察组血压、HR比对照组更低,差异有统计学意义(P<0.05);观察组治疗总有效率(97.73%)比对照组(81.82%)更高,差异有统计学意义(χ^(2)=4.456,P<0.05);观察组ADR与对照组比较,差异无统计学意义(P>0.05)。结论对轻、中度EH患者采用左旋氨氯地平+缬沙坦,可以增强疗效,有效调控血压水平,安全性高。
Objective To evaluate the clinical efficacy of levamlodipine+valsartan in patients with mild to moderate essential hypertension(EH).Methods A total of 88 patients with mild to moderate EH admitted to the Cardiovascular Department of Weifang Second People′s Hospital from January 2021 to March 2022 were conveniently selected as the research object and divided into control group(44 cases,treated with levamlodipine)and observation group(44 cases,treated with levamlodipine+valsartan)by random number table method.Blood pressure,heart rate(HR),treatment response rate and adverse drug reaction(ADR)were compared between groups.Results After 3 months of treatment,the blood pressure and HR in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).The total effective rate of observation group(97.73%)was higher than that of control group(81.82%),and the difference was statistically significant(χ^(2)=4.456,P<0.05).There was no significant difference in ADR between observation group and control group(P>0.05).Conclusion The use of levamlodipine+valsartan in patients with mild to moderate EH can enhance the curative effect,effectively regulate the blood pressure level,and has high safety.
作者
王阿兰
窦全玲
杨光
尹霞
王惠卿
WANG Alan;DOU Quanling;YANG Guang;YIN Xia;WANG Huiqing(Drug Clinical Research Center&Department of Cardiovascular Medicine,Weifang Second People′s Hospital,Weifang,Shandong Province,261041 China;Department of Anesthesiology,Weifang Second People′s Hospital,Weifang,Shandong Province,261041 China;Department of Science and Education,Weifang Second People′s Hospital,Weifang,Shandong Province,261041 China;Department of Neurology,Weifang Second People′s Hospital,Weifang,Shandong Province,261041 China;Nursing Department,Weifang Municipal Organ Hospital,Weifang,Shandong Province,261071 China)
出处
《中外医疗》
2023年第18期141-144,共4页
China & Foreign Medical Treatment
基金
潍坊市科技发展计划项目(2021YX069)。
